2025 Q4 -tulosraportti
10 päivää sitten
‧1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,75%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 106 621
Myynti
Määrä
2 063 762
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 320 | - | - | ||
| 10 | - | - | ||
| 425 | - | - | ||
| 1 550 | - | - | ||
| 400 | - | - |
Ylin
314,85VWAP
Alin
308,5VaihtoMäärä
1 729,1 5 552 349
VWAP
Ylin
314,85Alin
308,5VaihtoMäärä
1 729,1 5 552 349
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
2 t sitten2 t sittenA bit ” shy” but over all positive outlook from Doustdar. ELY Lilly CEO expects Medicare access to obesity treatments happen around June, which will boost the sales, Mike D is a bit more cautious in his prediction. Here are key points: Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn’t expect Medicare access to obesity treatments, expected later this year, to open up overnight. Doustdar said Medicare coverage, along with the launch of Novo’s new obesity pill and other factors, should help the company gradually boost prescription volumes and offset lower prices in the U.S. following a landmark drug pricing deal with Trump. You find the rest here: https://www.cnbc.com/2026/02/11/novo-nordisk-ceo-medicare-coverage-opens-15-million-patient-opportunity.html?utm_source=www.carbonfinance.io&utm_medium=newsletter&utm_campaign=19-ai-resilient-stocks&_bhlid=cd20d5ac63a7da1ccb6422a5305129583ba1778b
·2 t sittenIn 2026, a new word has been added to The Danish Dictionary: Novoholic n. 1. A person with an obsessive relationship with the Novo Nordisk stock; one who constantly updates the price, analyzes the market, and calculates 'what if I had bought more in...'. 2. (informal) An investor whose mood fluctuates with OMXC25 – but mostly with NVO. ⸻ A Novoholic is recognized by: • Unlocking the phone 'completely automatically' to check the price. • The words Wegovy, pipeline, and guidance being part of daily small talk. • Lunch break coinciding with the stock market opening in the USA. • Family dinners including the phrase: 'It's a long-term case, you know.' Typical utterances: • 'It's just a healthy correction.' • 'I'm in it for the fundamentals.' • 'Have you seen premarket?' • 'I'm not selling. I'm an investor, not a trader.' (checks the price 14 times an hour). Side effects: • Increased pulse from push notifications. • Conviction of being able to explain global obesity medicine in 30 seconds. • Slight euphoria with green figures. Existential doubt with red ones. Example: 'I'm not addicted, you know,' he said, updating the price again. 'I'm just following the market.' Antonyms: index buyer, passive investor. Related words: price junkie, portfolio patriot, stock optimist.
·4 t sittenBased on Friday's new prescription figures, what are your expectations for the development in the coming week?
·3 t sittenHe said that it surprised on the positive side.- ·6 t sittenWe Danes apparently do best when we are understated. We saw that in 1992, when Denmark, as a reserve team, was called into the European Championship at the last minute and ended up winning the entire tournament. No one expected anything. And perhaps that's precisely why it succeeded. Novo's announcements about 2026 have a bit of the same tone. Less jubilant optimism. More realism. There is talk of headwinds, market dynamics, and the need for focus. It is sober and without grand gestures. Perhaps it is actually a position of strength. When expectations are adjusted, and attention shifts from narrative to action. When more work is done than promised. We have previously shown that we perform best when we don't proclaim ourselves as favorites. Perhaps 2026 will not be the year for big headlines. Perhaps it will be the year when the foundation is strengthened, and the results speak for themselves.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
10 päivää sitten
‧1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,75%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 2 t sitten2 t sittenA bit ” shy” but over all positive outlook from Doustdar. ELY Lilly CEO expects Medicare access to obesity treatments happen around June, which will boost the sales, Mike D is a bit more cautious in his prediction. Here are key points: Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn’t expect Medicare access to obesity treatments, expected later this year, to open up overnight. Doustdar said Medicare coverage, along with the launch of Novo’s new obesity pill and other factors, should help the company gradually boost prescription volumes and offset lower prices in the U.S. following a landmark drug pricing deal with Trump. You find the rest here: https://www.cnbc.com/2026/02/11/novo-nordisk-ceo-medicare-coverage-opens-15-million-patient-opportunity.html?utm_source=www.carbonfinance.io&utm_medium=newsletter&utm_campaign=19-ai-resilient-stocks&_bhlid=cd20d5ac63a7da1ccb6422a5305129583ba1778b
- ·2 t sittenIn 2026, a new word has been added to The Danish Dictionary: Novoholic n. 1. A person with an obsessive relationship with the Novo Nordisk stock; one who constantly updates the price, analyzes the market, and calculates 'what if I had bought more in...'. 2. (informal) An investor whose mood fluctuates with OMXC25 – but mostly with NVO. ⸻ A Novoholic is recognized by: • Unlocking the phone 'completely automatically' to check the price. • The words Wegovy, pipeline, and guidance being part of daily small talk. • Lunch break coinciding with the stock market opening in the USA. • Family dinners including the phrase: 'It's a long-term case, you know.' Typical utterances: • 'It's just a healthy correction.' • 'I'm in it for the fundamentals.' • 'Have you seen premarket?' • 'I'm not selling. I'm an investor, not a trader.' (checks the price 14 times an hour). Side effects: • Increased pulse from push notifications. • Conviction of being able to explain global obesity medicine in 30 seconds. • Slight euphoria with green figures. Existential doubt with red ones. Example: 'I'm not addicted, you know,' he said, updating the price again. 'I'm just following the market.' Antonyms: index buyer, passive investor. Related words: price junkie, portfolio patriot, stock optimist.
- ·4 t sittenBased on Friday's new prescription figures, what are your expectations for the development in the coming week?·3 t sittenHe said that it surprised on the positive side.
- ·6 t sittenWe Danes apparently do best when we are understated. We saw that in 1992, when Denmark, as a reserve team, was called into the European Championship at the last minute and ended up winning the entire tournament. No one expected anything. And perhaps that's precisely why it succeeded. Novo's announcements about 2026 have a bit of the same tone. Less jubilant optimism. More realism. There is talk of headwinds, market dynamics, and the need for focus. It is sober and without grand gestures. Perhaps it is actually a position of strength. When expectations are adjusted, and attention shifts from narrative to action. When more work is done than promised. We have previously shown that we perform best when we don't proclaim ourselves as favorites. Perhaps 2026 will not be the year for big headlines. Perhaps it will be the year when the foundation is strengthened, and the results speak for themselves.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 106 621
Myynti
Määrä
2 063 762
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 320 | - | - | ||
| 10 | - | - | ||
| 425 | - | - | ||
| 1 550 | - | - | ||
| 400 | - | - |
Ylin
314,85VWAP
Alin
308,5VaihtoMäärä
1 729,1 5 552 349
VWAP
Ylin
314,85Alin
308,5VaihtoMäärä
1 729,1 5 552 349
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2025 Q4 -tulosraportti
10 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
3,75%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 2 t sitten2 t sittenA bit ” shy” but over all positive outlook from Doustdar. ELY Lilly CEO expects Medicare access to obesity treatments happen around June, which will boost the sales, Mike D is a bit more cautious in his prediction. Here are key points: Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn’t expect Medicare access to obesity treatments, expected later this year, to open up overnight. Doustdar said Medicare coverage, along with the launch of Novo’s new obesity pill and other factors, should help the company gradually boost prescription volumes and offset lower prices in the U.S. following a landmark drug pricing deal with Trump. You find the rest here: https://www.cnbc.com/2026/02/11/novo-nordisk-ceo-medicare-coverage-opens-15-million-patient-opportunity.html?utm_source=www.carbonfinance.io&utm_medium=newsletter&utm_campaign=19-ai-resilient-stocks&_bhlid=cd20d5ac63a7da1ccb6422a5305129583ba1778b
- ·2 t sittenIn 2026, a new word has been added to The Danish Dictionary: Novoholic n. 1. A person with an obsessive relationship with the Novo Nordisk stock; one who constantly updates the price, analyzes the market, and calculates 'what if I had bought more in...'. 2. (informal) An investor whose mood fluctuates with OMXC25 – but mostly with NVO. ⸻ A Novoholic is recognized by: • Unlocking the phone 'completely automatically' to check the price. • The words Wegovy, pipeline, and guidance being part of daily small talk. • Lunch break coinciding with the stock market opening in the USA. • Family dinners including the phrase: 'It's a long-term case, you know.' Typical utterances: • 'It's just a healthy correction.' • 'I'm in it for the fundamentals.' • 'Have you seen premarket?' • 'I'm not selling. I'm an investor, not a trader.' (checks the price 14 times an hour). Side effects: • Increased pulse from push notifications. • Conviction of being able to explain global obesity medicine in 30 seconds. • Slight euphoria with green figures. Existential doubt with red ones. Example: 'I'm not addicted, you know,' he said, updating the price again. 'I'm just following the market.' Antonyms: index buyer, passive investor. Related words: price junkie, portfolio patriot, stock optimist.
- ·4 t sittenBased on Friday's new prescription figures, what are your expectations for the development in the coming week?·3 t sittenHe said that it surprised on the positive side.
- ·6 t sittenWe Danes apparently do best when we are understated. We saw that in 1992, when Denmark, as a reserve team, was called into the European Championship at the last minute and ended up winning the entire tournament. No one expected anything. And perhaps that's precisely why it succeeded. Novo's announcements about 2026 have a bit of the same tone. Less jubilant optimism. More realism. There is talk of headwinds, market dynamics, and the need for focus. It is sober and without grand gestures. Perhaps it is actually a position of strength. When expectations are adjusted, and attention shifts from narrative to action. When more work is done than promised. We have previously shown that we perform best when we don't proclaim ourselves as favorites. Perhaps 2026 will not be the year for big headlines. Perhaps it will be the year when the foundation is strengthened, and the results speak for themselves.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 106 621
Myynti
Määrä
2 063 762
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 320 | - | - | ||
| 10 | - | - | ||
| 425 | - | - | ||
| 1 550 | - | - | ||
| 400 | - | - |
Ylin
314,85VWAP
Alin
308,5VaihtoMäärä
1 729,1 5 552 349
VWAP
Ylin
314,85Alin
308,5VaihtoMäärä
1 729,1 5 552 349
Välittäjätilasto
Dataa ei löytynyt